Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 2017 Jan;17(1):180-190.
doi: 10.1111/ajt.13886. Epub 2016 Jul 12.

Efficacy and Safety Outcomes of Extended Criteria Donor Kidneys by Subtype: Subgroup Analysis of BENEFIT-EXT at 7 Years After Transplant

S Florman  1 , T Becker  2 , B Bresnahan  3 , A Chevaile-Ramos  4 , D Carvalho  5 , G Grannas  6 , F Muehlbacher  7 , P J O'Connell  8 , H U Meier-Kriesche  9 , C P Larsen  10
Affiliations
Clinical Trial

Efficacy and Safety Outcomes of Extended Criteria Donor Kidneys by Subtype: Subgroup Analysis of BENEFIT-EXT at 7 Years After Transplant

S Florman et al. Am J Transplant. 2017 Jan.

Abstract

The phase III Belatacept Evaluation of Nephroprotection and Efficacy as First-Line Immunosuppression Trial-Extended Criteria Donors Trial (BENEFIT-EXT) study compared more or less intensive belatacept-based immunosuppression with cyclosporine (CsA)-based immunosuppression in recipients of extended criteria donor kidneys. In this post hoc analysis, patient outcomes were assessed according to donor kidney subtype. In total, 68.9% of patients received an expanded criteria donor kidney (United Network for Organ Sharing definition), 10.1% received a donation after cardiac death kidney, and 21.0% received a kidney with an anticipated cold ischemic time ≥24 h. Over 7 years, time to death or graft loss was similar between belatacept- and CsA-based immunosuppression, regardless of donor kidney subtype. In all three donor kidney cohorts, estimated mean GFR increased over months 1-84 for belatacept-based treatment but declined for CsA-based treatment. The estimated differences in GFR significantly favored each belatacept-based regimen versus the CsA-based regimen in the three subgroups (p < 0.0001 for overall treatment effect). No differences in the safety profile of belatacept were observed by donor kidney subtype.

Keywords: calcineurin inhibitor: cyclosporine A (CsA); clinical research/practice; donors and donation: deceased; donors and donation: donation after circulatory death (DCD); donors and donation: extended criteria; immunosuppressant; kidney transplantation/nephrology.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Patient numbers by donor kidney subgroup and treatment allocation. CIT, cold ischemia time; CsA, cyclosporine; DCD, donation after cardiac death; ECD, expanded criteria donor; LI, less intensive; MI, more intensive; UNOS, United Network for Organ Sharing.
Figure 2
Figure 2
Kaplan–Meier curve for the composite end point of time to death or graft loss in the (A) UNOS ECD, (B) DCD, and (C) anticipated CIT ≥24 h cohorts. CI, confidence interval; CIT, cold ischemia time; CsA, cyclosporine; DCD, donation after cardiac death; ECD, expanded criteria donor; HR, hazard ratio; LI, less intensive; MI, more intensive; UNOS, United Network for Organ Sharing.
Figure 3
Figure 3
Estimated mean GFR for months 1–84 (mixed‐effects modeling without imputation) in the (A) UNOS ECD, (B) DCD and (C) anticipated CIT ≥24 h cohorts. Data represent means and 95% CIs. CI, confidence interval; CIT, cold ischemia time; CsA, cyclosporine; DCD, donation after cardiac death; ECD, expanded criteria donor; LI, less intensive; MI, more intensive; UNOS, United Network for Organ Sharing.
See this image and copyright information in PMC

References

    1. Wolfe RA, Ashby VB, Milford EL, Ojo AO, Ettenger RE, Held PJ, et al. Comparison of mortality in all patients on dialysis, patients on dialysis awaiting transplantation, and recipients of a first cadaveric transplant. N Engl J Med 1999; 341: 1725–1730. - PubMed
    1. Ojo AO, Hanson JA, Meier‐Kriesche H, et al. Survival in recipients of marginal cadaveric donor kidneys compared with other recipients and wait listed candidates. J Am Soc Nephrol 2001; 12: 589–597. - PubMed
    1. Niu SF, Li IC. Quality of life of patients having renal replacement therapy. J Adv Nurs 2005; 51: 15–21. - PubMed
    1. Cohen B, Smits JM, Haase B, Persijn G, Vanrenterghem Y, Frei U. Expanding the donor pool to increase renal transplantation. Nephrol Dial Transplant 2005; 20: 34–41. - PubMed
    1. Organ Procurement and Transplantation Network (OPTN) and Scientific Registry of Transplant Recipients (SRTR) . OPTN/SRTR 2012 Annual Data Report. Rockville, MD: Department of Health and Human Services, Health Resources and Services Administration; 2014. [cited 2015 Feb 4]. Available from: http://onlinelibrary.wiley.com/doi/10.1111/ajt.v14.s1/issuetoc. - DOI

Publication types